Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Phacoemulsification | 11 | 2021 | 69 | 2.240 |
Why?
|
| Lenses, Intraocular | 7 | 2021 | 96 | 2.100 |
Why?
|
| Keratomileusis, Laser In Situ | 10 | 2021 | 35 | 1.870 |
Why?
|
| Lens Implantation, Intraocular | 12 | 2021 | 152 | 1.720 |
Why?
|
| Visual Acuity | 11 | 2019 | 236 | 1.640 |
Why?
|
| Refraction, Ocular | 9 | 2021 | 61 | 1.410 |
Why?
|
| Myopia | 5 | 2019 | 27 | 1.370 |
Why?
|
| Cataract | 4 | 2021 | 134 | 0.980 |
Why?
|
| Aberrometry | 2 | 2020 | 5 | 0.880 |
Why?
|
| Cataract Extraction | 3 | 2008 | 127 | 0.770 |
Why?
|
| Emmetropia | 1 | 2019 | 2 | 0.690 |
Why?
|
| Intraoperative Care | 1 | 2020 | 91 | 0.680 |
Why?
|
| Vision, Binocular | 1 | 2019 | 30 | 0.670 |
Why?
|
| Endothelium, Corneal | 4 | 2011 | 20 | 0.610 |
Why?
|
| Ultrasonic Therapy | 2 | 2008 | 19 | 0.550 |
Why?
|
| Postoperative Complications | 7 | 2009 | 1615 | 0.500 |
Why?
|
| Ketorolac Tromethamine | 5 | 2006 | 16 | 0.460 |
Why?
|
| Astigmatism | 3 | 2019 | 17 | 0.430 |
Why?
|
| Cornea | 6 | 2019 | 76 | 0.430 |
Why?
|
| Uveitis, Anterior | 3 | 2011 | 15 | 0.430 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2006 | 240 | 0.420 |
Why?
|
| Refractive Surgical Procedures | 5 | 2007 | 16 | 0.400 |
Why?
|
| Patient Satisfaction | 3 | 2009 | 378 | 0.360 |
Why?
|
| Prospective Studies | 9 | 2019 | 3705 | 0.360 |
Why?
|
| Contrast Sensitivity | 2 | 2007 | 28 | 0.310 |
Why?
|
| Ophthalmology | 2 | 2005 | 39 | 0.300 |
Why?
|
| Prosthesis Design | 4 | 2019 | 301 | 0.300 |
Why?
|
| Vision Disorders | 1 | 2007 | 94 | 0.280 |
Why?
|
| Surgical Flaps | 6 | 2005 | 120 | 0.240 |
Why?
|
| Humans | 31 | 2021 | 68618 | 0.240 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 4848 | 0.230 |
Why?
|
| Drug Residues | 1 | 2003 | 6 | 0.230 |
Why?
|
| Detergents | 1 | 2003 | 34 | 0.230 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2005 | 504 | 0.220 |
Why?
|
| Middle Aged | 19 | 2019 | 21147 | 0.220 |
Why?
|
| Aged | 15 | 2019 | 14862 | 0.220 |
Why?
|
| Prednisolone | 3 | 2011 | 23 | 0.210 |
Why?
|
| Biometry | 2 | 2021 | 72 | 0.210 |
Why?
|
| Double-Blind Method | 6 | 2011 | 1738 | 0.200 |
Why?
|
| Intraocular Pressure | 5 | 2011 | 143 | 0.190 |
Why?
|
| Optics and Photonics | 1 | 2021 | 29 | 0.190 |
Why?
|
| Intraoperative Complications | 3 | 2009 | 129 | 0.180 |
Why?
|
| Glucocorticoids | 3 | 2011 | 222 | 0.180 |
Why?
|
| Corneal Stroma | 4 | 2004 | 20 | 0.180 |
Why?
|
| Keratitis | 4 | 2004 | 20 | 0.180 |
Why?
|
| Retrospective Studies | 6 | 2021 | 7277 | 0.180 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2019 | 52 | 0.160 |
Why?
|
| Refractive Errors | 3 | 2007 | 24 | 0.160 |
Why?
|
| Treatment Outcome | 7 | 2016 | 7029 | 0.150 |
Why?
|
| Female | 18 | 2019 | 38074 | 0.140 |
Why?
|
| Male | 16 | 2019 | 37321 | 0.130 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 3 | 2004 | 19 | 0.130 |
Why?
|
| Photorefractive Keratectomy | 2 | 2005 | 12 | 0.120 |
Why?
|
| Corneal Ulcer | 2 | 2005 | 10 | 0.120 |
Why?
|
| Postoperative Period | 3 | 2011 | 238 | 0.110 |
Why?
|
| Ophthalmic Solutions | 4 | 2006 | 39 | 0.110 |
Why?
|
| Cell Count | 3 | 2011 | 248 | 0.110 |
Why?
|
| Fluprednisolone | 1 | 2011 | 2 | 0.100 |
Why?
|
| Corneal Edema | 1 | 2011 | 4 | 0.100 |
Why?
|
| Disease Models, Animal | 5 | 2006 | 2550 | 0.090 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2009 | 39 | 0.080 |
Why?
|
| Iris Diseases | 1 | 2009 | 8 | 0.080 |
Why?
|
| Iris | 1 | 2009 | 27 | 0.080 |
Why?
|
| Hyperopia | 1 | 2009 | 14 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 32 | 0.080 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 20 | 0.080 |
Why?
|
| Rabbits | 6 | 2006 | 509 | 0.080 |
Why?
|
| Adult | 12 | 2009 | 21403 | 0.080 |
Why?
|
| Lasers, Excimer | 2 | 2005 | 10 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2011 | 706 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2009 | 141 | 0.080 |
Why?
|
| Pupil | 2 | 2007 | 51 | 0.070 |
Why?
|
| Staphylococcus aureus | 2 | 2006 | 175 | 0.070 |
Why?
|
| Acrylates | 1 | 2007 | 17 | 0.070 |
Why?
|
| Nedocromil | 2 | 2004 | 7 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2006 | 47 | 0.070 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2006 | 3 | 0.070 |
Why?
|
| Conjunctivitis | 1 | 2006 | 6 | 0.070 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2006 | 15 | 0.070 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2006 | 18 | 0.070 |
Why?
|
| Endophthalmitis | 1 | 2006 | 15 | 0.070 |
Why?
|
| Keratoplasty, Penetrating | 1 | 2005 | 6 | 0.070 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2005 | 6 | 0.070 |
Why?
|
| Eye Infections, Fungal | 1 | 2005 | 7 | 0.070 |
Why?
|
| Dry Eye Syndromes | 1 | 2005 | 12 | 0.070 |
Why?
|
| Fluoroquinolones | 1 | 2006 | 49 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2006 | 62 | 0.070 |
Why?
|
| Disease Transmission, Infectious | 1 | 2005 | 25 | 0.060 |
Why?
|
| Cryptococcosis | 1 | 2005 | 28 | 0.060 |
Why?
|
| Sensation | 1 | 2005 | 49 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2005 | 403 | 0.060 |
Why?
|
| Keratectomy, Subepithelial, Laser-Assisted | 1 | 2005 | 3 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 156 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2006 | 453 | 0.060 |
Why?
|
| Inflammation | 2 | 2011 | 1030 | 0.060 |
Why?
|
| Cadaver | 1 | 2004 | 136 | 0.060 |
Why?
|
| Cyclopentolate | 1 | 2003 | 3 | 0.060 |
Why?
|
| Mydriatics | 1 | 2003 | 4 | 0.060 |
Why?
|
| Eye Injuries | 1 | 2004 | 18 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2005 | 195 | 0.060 |
Why?
|
| Corneal Neovascularization | 1 | 2003 | 6 | 0.060 |
Why?
|
| Porphyrins | 1 | 2003 | 15 | 0.060 |
Why?
|
| Mycobacterium chelonae | 1 | 2003 | 9 | 0.060 |
Why?
|
| Stainless Steel | 1 | 2003 | 31 | 0.060 |
Why?
|
| Eye Infections, Bacterial | 1 | 2003 | 15 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 32 | 0.060 |
Why?
|
| Solutions | 1 | 2003 | 115 | 0.060 |
Why?
|
| Biological Factors | 1 | 2003 | 11 | 0.050 |
Why?
|
| Corneal Diseases | 1 | 2003 | 12 | 0.050 |
Why?
|
| Amnion | 1 | 2003 | 15 | 0.050 |
Why?
|
| Blister | 1 | 2003 | 16 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2003 | 59 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2003 | 152 | 0.050 |
Why?
|
| Health Surveys | 1 | 2005 | 489 | 0.050 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2003 | 37 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2005 | 2800 | 0.050 |
Why?
|
| Time Factors | 2 | 2008 | 4655 | 0.050 |
Why?
|
| Titanium | 1 | 2003 | 118 | 0.050 |
Why?
|
| Water | 1 | 2003 | 230 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 214 | 0.050 |
Why?
|
| Androstadienes | 1 | 2002 | 41 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 629 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2003 | 1040 | 0.050 |
Why?
|
| Quality of Life | 1 | 2009 | 1515 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2002 | 234 | 0.040 |
Why?
|
| Corneal Pachymetry | 1 | 2019 | 5 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 1026 | 0.040 |
Why?
|
| Safety | 3 | 2004 | 145 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 3259 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2004 | 133 | 0.040 |
Why?
|
| Equipment Design | 1 | 2019 | 500 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 1173 | 0.040 |
Why?
|
| Lipopolysaccharides | 3 | 2004 | 455 | 0.040 |
Why?
|
| United States | 2 | 2005 | 7367 | 0.030 |
Why?
|
| Staining and Labeling | 2 | 2005 | 144 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2007 | 275 | 0.030 |
Why?
|
| Animals | 6 | 2006 | 20881 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2011 | 5 | 0.020 |
Why?
|
| Lasers, Solid-State | 1 | 2009 | 8 | 0.020 |
Why?
|
| Pseudophakia | 1 | 2009 | 27 | 0.020 |
Why?
|
| Laser Therapy | 1 | 2009 | 54 | 0.020 |
Why?
|
| Bibliometrics | 1 | 2009 | 25 | 0.020 |
Why?
|
| Syndrome | 1 | 2009 | 255 | 0.020 |
Why?
|
| Global Health | 1 | 2009 | 136 | 0.020 |
Why?
|
| Risk Factors | 2 | 2009 | 5731 | 0.020 |
Why?
|
| Anterior Chamber | 1 | 2007 | 20 | 0.020 |
Why?
|
| Instillation, Drug | 1 | 2006 | 15 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2006 | 111 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 164 | 0.020 |
Why?
|
| Tears | 1 | 2005 | 9 | 0.020 |
Why?
|
| Conjunctiva | 1 | 2005 | 16 | 0.020 |
Why?
|
| Incidence | 1 | 2009 | 1603 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2005 | 249 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2004 | 11 | 0.010 |
Why?
|
| Geography | 1 | 2004 | 80 | 0.010 |
Why?
|
| Adolescent | 2 | 2009 | 8912 | 0.010 |
Why?
|
| Equipment Safety | 1 | 2004 | 50 | 0.010 |
Why?
|
| Reoperation | 1 | 2005 | 467 | 0.010 |
Why?
|
| Analgesia | 1 | 2004 | 58 | 0.010 |
Why?
|
| Ciliary Body | 1 | 2003 | 52 | 0.010 |
Why?
|
| Anterior Eye Segment | 1 | 2003 | 13 | 0.010 |
Why?
|
| Clarithromycin | 1 | 2003 | 11 | 0.010 |
Why?
|
| Amikacin | 1 | 2003 | 13 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 137 | 0.010 |
Why?
|
| Bodily Secretions | 1 | 2003 | 3 | 0.010 |
Why?
|
| Ofloxacin | 1 | 2003 | 15 | 0.010 |
Why?
|
| Meibomian Glands | 1 | 2003 | 4 | 0.010 |
Why?
|
| Soaps | 1 | 2003 | 5 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 63 | 0.010 |
Why?
|
| Exotoxins | 1 | 2003 | 4 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2003 | 30 | 0.010 |
Why?
|
| Epithelium, Corneal | 1 | 2003 | 3 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 328 | 0.010 |
Why?
|
| Lasers | 1 | 2003 | 61 | 0.010 |
Why?
|
| Biological Dressings | 1 | 2003 | 4 | 0.010 |
Why?
|
| Povidone-Iodine | 1 | 2003 | 16 | 0.010 |
Why?
|
| Tobramycin | 1 | 2003 | 38 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 2003 | 49 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 215 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 163 | 0.010 |
Why?
|
| Debridement | 1 | 2003 | 55 | 0.010 |
Why?
|
| Loteprednol Etabonate | 1 | 2002 | 4 | 0.010 |
Why?
|
| Foreign-Body Reaction | 1 | 2002 | 24 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 252 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2003 | 166 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 649 | 0.010 |
Why?
|
| Cell Survival | 1 | 2004 | 901 | 0.010 |
Why?
|
| Pain Management | 1 | 2003 | 186 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 2077 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 3187 | 0.010 |
Why?
|